Alzheimer’s drug trial sparks excitement

An experimental drug has generated intense interest as a potential future treatment for Alzheimer’s, with results from a small trial showing it dramatically reduces amyloid with virtually no side effects.

Merck’s verubecestat, a BACE1 inhibitor, reduced the production of amyloid beta by over 90% in phase 1 results published today.

“It’s really the first molecule of its kind to combine Ab[amyloid-beta]